Clinical Research Directory

Inclusion Criteria: * Men and women, 21-99 years of age and any race * Normal left ventricular function (left ventricular ejection fraction (LVEF) \>50%) as determined by echocardiography * HER2 positive or negative breast cancer patients or lymphoma patients * Designated to receive standard of care (SOC) treatment with an anthracycline-containing regimen including combination therapy * Patients willing to adhere to fasting for 15 hours before 18F-FDG PET imaging studies (if applicable) Exclusion Criteria: * Inability to receive and sign informed consent * Prior exposure to anthracyclines or other cardiotoxic drug * Contraindications to anthracycline chemotherapy * Patients with history of myocardial infarction * Patients with fasting blood sugar \>200 mg/dL or \<70 mg/dL and symptomatic * Contraindications to MR imaging (ferromagnetic implants, pacemaker, brain aneurysm clips, shrapnel, claustrophobia, etc.) * Pregnant or lactating. All female subjects of childbearing potential must have a documented negative pregnancy test (serum or urine hCG) performed within 24 hours immediately prior to the administration of 68Ga-Galmydar or documented post-menopausal defined as the cessation of menses for ≥ 12 months or documentation of having a bilateral oophorectomy and/or hysterectomy. * Any condition that in the opinion of the Principal Investigator or designee could increase risk to the participant, limit the participant's ability to tolerate the research procedures or interfere with collection of the data such as: * Inability to lie still or unable to tolerate a supine position with arms up over the head or down at sides for up to a 60-minute PET scan due to chronic back/shoulder pain or arthritis as assessed by physical examination and/or medical history